Aktis Oncology, Inc. (AKTS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-16

Key Insights

Aktis Oncology appointed an experienced pharmaceutical executive, Glenn Gormley, MD, PhD, to its board of directors, which could strengthen the company's clinical development and commercialization capabilities.
Two existing board members, Helen S. Kim and Oleg Nodelman, have announced their resignations, potentially signaling a change in the company's strategic direction or shareholder representation.
The company granted Gormley stock options as part of his board compensation, aligning his interests with those of shareholders.

Want the newest filings?

This analysis covers the filing from 2026-04-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-31

Aktis Oncology reported its full-year 2025 financial results, providing an update on the company's business operations.
The company did not disclose any specific financial metrics or performance figures in the 8-K filing, limiting the ability to assess its operational and financial health.
Without detailed financial information, it is difficult to determine the overall significance of this update for investors.

Filed: 2026-01-12

Aktis Oncology, Inc. (AKTS) has filed an 8-K disclosing amendments to its certificate of incorporation and bylaws, including the authorization of additional shares of common and preferred stock, the establishment of a classified board, and new provisions related to stockholder proposals and director nominations.
The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
The amendments to the certificate of incorporation and bylaws indicate potential changes to Aktis Oncology's corporate governance structure and shareholder rights, which investors should closely monitor.

Other reports for Aktis Oncology, Inc.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.